B1085-32C
CAS Number
153559-49-0Grade
Highly PurifiedMolecular Formula
C24H28O2Molecular Weight
348.48EU Commodity Code
38220090Shipping Temp
Blue IceStorage Temp
-20°CBexarotene, Free Acid (Targretin, Targretyn, Targrexin, LGD-1069, LG 1069, LG100069, SR-11247)
4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic Acid; LG 100069; LG 1069; LG 69; LGD 1069; RO 26-4455; SR 11247; Targret; Targretin; Targretyn; Targrexin
Bexarotene (LGD-1069) is a synthetic retinoid analog with specific affinity for the retinoid X receptor and belongs to a group of compounds called rexinoids. It is an oral, noncytotoxic drug that was approved in Europe and in the U.S.A. for the treatment of refractory advanced-stage cutaneous T-cell lymphomas (CTCL).
Synonyms
4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic Acid; LG 100069; LG 1069; LG 69; LGD 1069; RO 26-4455; SR 11247; Targret; Targretin; Targretyn; Targrexin
Molecular Formula
C24H28O2
Appearance
White to off-white solid
Solubility
DMSO (50mg/ml, clear, colorless solution); Soluble in ethanol at 10mg/ml with warming; very poorly soluble in water. Maximum solubility in plain water is estimated to be about 10-50uM.
Storage and Stability
Store at -20°C under inert atmosphere. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. Gniadecki, R., et al. "The optimal use of bexarotene in cutaneous T-cell lymphoma." Br. J. Dermatol. 157:433-440 (2007). 2. Rigas, J.R. and Dragnev, K.H. "Emerging Role of Rexinoids in Non-Small Cell Lung Cancer: Focus on Bexarotene." The Oncologist 10:22-33 (2005). 3. Wu, K., et al. "The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice." Cancer Res. 62:6376-6380 (2002). 3. Ye,n W.C. and Lamph, W.W. "A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer." Prostate 66:305-316 (2006). 4. Yen, W.C. and Lamph, W.W. "The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma." Mol. Cancer Ther. 4:824-834 (2005). 5. Yen, W.C., et al. "A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer." Clin. Cancer Res. 10:8656-8664 (2004).USBio References
No references available